Arimidex/Faslodex/Iressa Study: A Phase II Trial of Primary Systemic Therapy Using a Combination of Arimidex, Faslodex and Iressa (Gefitinib) in Postmenopausal Women With Hormone Receptor Positive Breast Cancer.

Trial Profile

Arimidex/Faslodex/Iressa Study: A Phase II Trial of Primary Systemic Therapy Using a Combination of Arimidex, Faslodex and Iressa (Gefitinib) in Postmenopausal Women With Hormone Receptor Positive Breast Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2013

At a glance

  • Drugs Anastrozole (Primary) ; Fulvestrant (Primary) ; Gefitinib (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Feb 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 Nov 2011 Planned end date changed from 1 Jan 2013 to 1 Jan 2012 as reported by ClinicalTrials.gov.
    • 01 Oct 2011 Results published in Breast Cancer Research and Treatment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top